---
title: "Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $65, Implies 16% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294940404.md"
description: "Travere Therapeutics' average 12-month price target was raised to $64.29 from $59.14 by 14 analysts, implying a ~15% upside based on the Aug. 4 close. The consensus rating remains 'Buy', with 14 buys, 1 hold, and 0 sells among covering analysts."
datetime: "2026-08-05T09:20:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294940404.md)
  - [en](https://longbridge.com/en/news/294940404.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294940404.md)
---

# Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $65, Implies 16% Upside

-   According to estimates from 14 analysts, Travere Therapeutics, Inc. stock's average price target has risen from $59.14 to $64.29, with forecasts ranging from $49 to $78 per share
-   Based on the Aug. 4 closing price, the updated target implies approximately 15% potential upside
-   Consensus rating remains at “Buy” across 15 covering analysts, with 14 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for Travere Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Travere Therapeutics, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [97,573 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Rice Hall James & Associates LLC](https://longbridge.com/en/news/296209446.md)
- [Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LP](https://longbridge.com/en/news/295633758.md)
- [Travere Therapeutics director Gary A. Lyons disposes of USD 629,150 in common shares](https://longbridge.com/en/news/296394692.md)
- [Travere Therapeutics posts corporate overview on rare kidney disease growth strategy, FILSPARI expansion and pipeline updates](https://longbridge.com/en/news/295857208.md)
- [If You Invested $1000 In Extra Space Storage Stock 20 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/296250257.md)